BIOLOGIC THERAPY WITH INTERLEUKIN-5 MONOCLONIC ANTIBODY MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS WITH UNDERLYING DISEASES

Abstract

The main goal of severe asthma treatment is to prevent exacerbations and hospitalization. However, recent data show that biologic therapy with anti-interleukin-5 monoclonal antibody mepolizumab may even help to achieve clinical remission in patients with severe eosinophilic asthma. It has been observed that treatment with mepolizumab is effective in managing severe asthma in patients with various underlying diseases. Moreover, mepolizumab is a choice of additive treatment in certain other eosinophilic diseases.